

Message

From: Rieth, Susan [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=00AAC63CC995489188B8A449AAA18F5E-RIETH, SUSAN]
Sent: 5/20/2014 2:39:45 PM
To: D'Amico, Louis [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=78a91f83c4414910be286efe02004dbc-D'Amico, Louis J.]; Subramaniam, Ravi [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e738f9d27062486e9047184b867fd968-Subramaniam, Ravi]; Blessinger, Todd [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f5240ca690c84f8fb20bac6fd7273fd5-Blessinger, Todd]
Subject: RDX -- progress on noncancer D-R section
Attachments: RDX_dose-response_revision of ICF ch2_shr_5-20-14.docx

Hi all,

Not that I'm forwarding a finished product, but just wanted to let you know where I stand on revisions to the noncancer section of chapter 2 (having started with the ICF version).

A couple of things...

Deliberative Process / Ex. 5

I'll keep tinkering with this version. Let me know if there's a more efficient way forward. I expect I'll move to cancer shortly, and also expect I'll have far fewer changes there. (Todd -- this is probably where we'll be overlapping the most).

Thanks,
Sue